Coordinated Financial Services Inc. Invests $222,000 in Pfizer Inc. $PFE

Coordinated Financial Services Inc. acquired a new position in shares of Pfizer Inc. (NYSE:PFE) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 9,150 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

A number of other institutional investors also recently made changes to their positions in the company. Coerente Capital Management boosted its stake in shares of Pfizer by 9.9% in the second quarter. Coerente Capital Management now owns 660,614 shares of the biopharmaceutical company’s stock valued at $16,013,000 after buying an additional 59,397 shares during the period. IFP Advisors Inc boosted its stake in shares of Pfizer by 6.1% in the second quarter. IFP Advisors Inc now owns 213,545 shares of the biopharmaceutical company’s stock valued at $5,220,000 after buying an additional 12,206 shares during the period. Callan Family Office LLC boosted its stake in shares of Pfizer by 230.6% in the second quarter. Callan Family Office LLC now owns 69,203 shares of the biopharmaceutical company’s stock valued at $1,677,000 after buying an additional 48,269 shares during the period. Leo Wealth LLC bought a new stake in shares of Pfizer in the second quarter valued at approximately $3,152,000. Finally, MSH Capital Advisors LLC boosted its stake in shares of Pfizer by 26.2% in the second quarter. MSH Capital Advisors LLC now owns 43,632 shares of the biopharmaceutical company’s stock valued at $1,058,000 after buying an additional 9,047 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Bank of America boosted their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a research note on Friday, October 3rd. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group reiterated a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a research note on Wednesday, October 1st. Morgan Stanley lowered their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and an average price target of $28.35.

Pfizer Stock Down 1.7%

Shares of PFE opened at $24.81 on Friday. The firm has a 50 day simple moving average of $24.86 and a two-hundred day simple moving average of $24.14. The company has a market cap of $141.03 billion, a P/E ratio of 13.19, a P/E/G ratio of 0.83 and a beta of 0.55. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. Pfizer Inc. has a one year low of $20.92 and a one year high of $29.82.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company’s revenue for the quarter was up 10.3% compared to the same quarter last year. During the same period in the prior year, the business earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.